Effect of dapagliflozin-spironolactone combination therapy versus monotherapy on albuminuria reduction and hyperkalemia risk in elderly patients with early type 2 diabetic nephropathy receiving high-dose RASi: A randomized controlled trial

American Journal of the Medical Sciences · Published 2026-05-20 · DOI 10.1016/j.amjms.2026.05.005

Authors (4)

Yingying Chen, Peng Liu, Lili Chen, Fengmei Zhang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Chen, Y., Liu, P., Chen, L., et al. (2026). Effect of dapagliflozin-spironolactone combination therapy versus monotherapy on albuminuria reduction and hyperkalemia risk in elderly patients with early type 2 diabetic nephropathy receiving high-dose RASi: A randomized controlled trial. American Journal of the Medical Sciences. https://doi.org/10.1016/j.amjms.2026.05.005

Related articles